Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPulmonologySierra Health and Life respiratory interleukins Co…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Modifiedsierra health and lifePolicy 2026D0055Y

    Respiratory Interleukins (Cinqair, Fasenra, & Nucala)

    Customize your policy alerts

    Sign up for sierra health and life Policy 2026D0055Y alerts

    Get alerted when Policy 2026D0055Y changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical benefit drug policy governing provider-administered use of reslizumab (Cinqair), benralizumab (Fasenra), and mepolizumab (Nucala) for treatment of severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis (EGPA); affects prescribing providers, prior authorization reviewers, and members under Sierra Health and Life plans.

    Policy Summary
    Payersierra health and life
    PolicyRespiratory Interleukins (Cinqair, Fasenra, & Nucala)
    Policy CodePolicy 2026D0055Y
    Change TypeAdded Review at Launch note for Exdensur™archived prior version
    Effective DateApr 1, 2026
    Next Review Date
    Key ActionObtain prior authorization with documentation of diagnosis, baseline eosinophil count, prior therapy trials, and prescriber specialty.
    SourceLink
    POLICY UPDATE CHANGES

    Added language that Exdensur™ (depemokimab-ulaa) has been added to the Review at Launch program and some members may not be eligible for coverage at this time.

    Archived previous policy version 2026D0055X.

    04/01/2026most recent revision
    FDA-listedindications described
    ≤12 monthsinitial auth
    ~1.2-2.4Mpeople with severe asthma (US)
    3biologics discussed

    Coverage Criteria for Cinqair, Fasenra, and Nucala

    Fasenra — EGPA (provider administration)

    Medically necessary when ALL of the following are met

    Fasenra for EGPA criteria

    • Diagnosis

      • EGPA diagnostic components: Diagnosis of EGPA; past medical history or presence of asthma; presence of at least two of the following typical EGPA characteristics: histopathological evidence (eosinophilic vasculitis, perivascular eosinophilic infiltration, or eosinophil-rich granulomatous inflammation)
    • Relapsing or refractory disease definition: Either relapsing disease (at least one EGPA relapse within the past 2 years requiring additional or dose escalation of corticosteroids or immunosuppressant, or hospitalization) OR refractory disease (failure to attain remission within the prior 6 months following induction treatment)
    Policy Summary
    Payersierra health and life
    PolicyRespiratory Interleukins (Cinqair, Fasenra, & Nucala)
    Policy CodePolicy 2026D0055Y
    Change TypeAdded Review at Launch note for Exdensur™archived prior version
    Effective DateApr 1, 2026
    Next Review Date
    Key ActionObtain prior authorization with documentation of diagnosis, baseline eosinophil count, prior therapy trials, and prescriber specialty.
    SourceLink
    On This Page
    Coverage Criteria for Cinqair, Fasenra, and NucalaBilling and Diagnosis CodesProvider Requirements, Prior Authorization, and DocumentationClinical Background and Evidence ContextKey Definitions and Phenotype CriteriaPolicy Revision History
    Concurrent therapy and prescribing:
    Patient is currently taking standard therapy (systemic glucocorticoids with or without immunosuppressive therapy); patient is not receiving Fasenra in combination with anti-IL-5 agents (e.g., Nucala, Cinqair), anti-IgE (e.g., omalizumab), anti-IL-4 (e.g., dupilumab), or TSLP inhibitors (e.g., tezepelumab); dosing is per FDA labeling; prescribed by pulmonologist, rheumatologist, or allergist/immunologist; initial authorization ≤ 12 months

    Nucala — EGPA (provider administration)

    Medically necessary when ALL of the following are met

    Nucala for EGPA criteria

    • Diagnosis

      • EGPA diagnostic components: Diagnosis of EGPA; past medical history or presence of asthma; presence of at least two of the following typical EGPA characteristics: histopathological evidence (eosinophilic vasculitis, perivascular eosinophilic infiltration, or eosinophil-rich granulomatous inflammation), neuropathy (mono or poly), pulmonary infiltrates (non-fixed), sino-nasal abnormality, cardiomyopathy, glomerulonephritis, alveolar hemorrhage, palpable purpura, or ANCA positive
    • Relapsing or refractory disease definition: Either relapsing disease (at least one EGPA relapse within the past 2 years requiring additional or dose escalation of corticosteroids or immunosuppressant, or hospitalization) OR refractory disease (failure to attain remission within the prior 6 months following induction treatment)
    • Concurrent therapy and prescribing: Patient is currently taking standard therapy (systemic glucocorticoids with or without immunosuppressive therapy); patient is not receiving Nucala in combination with anti-IL-5 agents (e.g., Cinqair, Fasenra), anti-IgE (e.g., omalizumab), anti-IL-4 (e.g., dupilumab), or TSLP inhibitors (e.g., tezepelumab); dosing is per FDA labeling; prescribed by pulmonologist, rheumatologist, or allergist/immunologist; initial authorization ≤ 12 months

    Cinqair — Severe asthma (provider administration)

    Medically necessary when ALL of the following are met

    Cinqair severe asthma criteria

    • Diagnosis and severity: Diagnosis of severe asthma AND classification as uncontrolled/inadequately controlled by at least one: poor symptom control (e.g., ACQ>1.5 or ACT<20), ≥2 systemic corticosteroid bursts (≥3 days) in prior 12 months, asthma-related emergency treatment/hospitalization, airflow limitation (post-bronchodilator FEV1 <80% predicted with reduced FEV1/FVC), or dependence on maintenance oral corticosteroids
    • Phenotype: Eosinophilic phenotype defined by baseline (pre-reslizumab) peripheral blood eosinophils ≥ 150 cells/μL
    • Concomitant controller therapy: Used in combination with a maximally-dosed ICS/LABA combination product or a maximally-dosed ICS plus an additional asthma controller medication
    • Prior biologic or Tezspire requirements: One of: history of failure to a 4-month trial of Fasenra or Nucala OR contraindication/intolerance to them; AND one of: history of failure to a 4-month trial of Tezspire OR contraindication/intolerance to Tezspire
    • Other: Not receiving Cinqair in combination with other biologics listed for the same indication (anti-IL-5, anti-IgE, anti-IL-4, TSLP inhibitors); dosing per FDA labeling; prescribed by pulmonologist or allergist/immunologist; initial authorization ≤ 12 months

    Fasenra — Severe asthma (provider administration)

    Medically necessary when ALL of the following are met

    Fasenra severe asthma criteria

    • Diagnosis and severity: Diagnosis of severe asthma AND classification as uncontrolled/inadequately controlled by at least one: poor symptom control (e.g., ACQ>1.5 or ACT<20), ≥2 systemic corticosteroid bursts (≥3 days) in prior 12 months, asthma-related emergency treatment/hospitalization, airflow limitation (post-bronchodilator FEV1 <80% predicted with reduced FEV1/FVC), or dependence on maintenance oral corticosteroids
    • Phenotype: Eosinophilic phenotype defined by baseline (pre-treatment) peripheral blood eosinophils ≥ 150 cells/μL
    • Concomitant controller therapy: Used in combination with a maximally-dosed ICS/LABA product or a maximally-dosed ICS plus an additional asthma controller medication
    • Other: Not receiving Fasenra in combination with other biologics listed for the same indication; dosing per FDA labeling; prescribed by pulmonologist or allergist/immunologist; initial authorization ≤ 12 months

    Nucala — Severe asthma (provider administration)

    Medically necessary when ALL of the following are met

    Nucala severe asthma criteria

    • Diagnosis and severity: Diagnosis of severe asthma AND classification as uncontrolled/inadequately controlled by at least one: poor symptom control (e.g., ACQ>1.5 or ACT<20), ≥2 systemic corticosteroid bursts (≥3 days) in prior 12 months, asthma-related emergency treatment/hospitalization, airflow limitation (post-bronchodilator FEV1 <80% predicted with reduced FEV1/FVC), or dependence on maintenance oral corticosteroids
    • Phenotype: Eosinophilic phenotype defined by baseline (pre-treatment) peripheral blood eosinophils ≥ 150 cells/μL
    • Concomitant controller therapy: Used in combination with a maximally-dosed ICS/LABA product or a maximally-dosed ICS plus an additional asthma controller medication
    • Other: Not receiving Nucala in combination with other biologics listed for the same indication; dosing per FDA labeling; prescribed by pulmonologist or allergist/immunologist; initial authorization ≤ 12 months

    Nucala — Severe eosinophilic asthma (initial)

    Covered when ALL of the following are met:

    Asthma baseline therapy and concomitant use: Patient is receiving a maximally-dosed ICS product and one additional asthma controller medication (examples provided)

    examples include ciclesonide, mometasone, beclomethasone; LABA or leukotriene receptor antagonist

    No concurrent biologic: Patient is not receiving Nucala in combination with anti-IL-5, anti-IgE, anti-IL-4, or TSLP inhibitors for the same indication

    see examples: reslizumab, benralizumab, omalizumab, dupilumab, tezepelumab

    Dosing and prescriber: Dosing per FDA labeling and prescribed by pulmonologist or allergist/immunologist

    Initial authorization ≤ 12 months

    Reauthorization — Cinqair, Fasenra, or Nucala for severe eosinophilic asthma

    Reauthorization approved when ALL of the following are met:

    Clinical response: Documentation of positive clinical response demonstrated by at least one: reduction in exacerbation frequency, decreased rescue medication use, increase in percent predicted FEV1 from pretreatment baseline, or reduction in symptom frequency/severity
    Concomitant ICS maintenance therapy: Used in combination with an ICS-containing maintenance medication

    examples provided

    No concurrent biologic therapy: Patient is not receiving the product in combination with another anti-IL-5 for the same indication (product-specific cross-exclusion)

    Reauthorization ≤ 12 months

    Nucala — Hypereosinophilic Syndrome (HES) (initial)

    Nucala is medically necessary when ALL of the following are met:

    Duration of diagnosis: Diagnosis of HES for ≥ 6 months
    Exclude secondary causes and molecular testing: No identifiable non-hematologic secondary cause of HES and HES is not FIP1L1-PDGFRα kinase-positive
    Baseline eosinophils and background therapy: Baseline (pre-mepolizumab) blood eosinophil level ≥ 1000 cells/µL within the past 4 weeks and patient on stable background HES therapy≥ 1000 cells/µL

    Medical records must be submitted

    No concurrent biologic and prescriber: Not receiving other biologics for same indication; dosing per FDA labeling; prescribed by allergist, immunologist, hematologist, cardiologist, or pulmonologist

    Initial authorization ≤ 12 months

    Reauthorization — Nucala for HES

    Reauthorization approved when ALL of the following are met:

    Clinical response: Documentation of positive clinical response demonstrated by at least one: reduction in HES flares or maintenance/reduction in background HES therapy requirements
    No concurrent biologic and dosing: Patient is not receiving other specified biologics for the same indication and dosing is per FDA labeling

    Reauthorization ≤ 12 months

    Nucala — Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) (initial)

    Nucala is proven/medically necessary when ALL of the following are met:

    Diagnosis and use: Diagnosis of CRSwNP and used as add-on maintenance therapy
    Prior inadequate response and symptoms duration: Inadequate response to nasal corticosteroids and two or more symptoms for >12 weeks (nasal mucopurulent discharge, nasal obstruction, facial pain/pressure/fullness, or reduction/loss of smell)
    Objective findings: One of: purulent mucus/edema in middle meatus/ethmoid, polyps in nasal cavity/middle meatus, or CT showing mucosal thickening or opacification

    Requires endoscopy or CT findings

    Polyp/surgical history: One of: presence of bilateral nasal polyposis or prior surgical removal of bilateral nasal polyps
    Prior interventions: One of: prior sinus surgery; systemic corticosteroids for CRSwNP in previous 2 years; or failure of two classes (saline irrigations, intranasal corticosteroids, antileukotrienes)
    Concomitant therapy and exclusions: Will receive Nucala with intranasal corticosteroids; not receiving other biologics for same indication; dosing per FDA label; prescribed by allergy/ENT/pulmonology

    Initial authorization ≤ 12 months

    Reauthorization — Nucala for CRSwNP

    Reauthorization approved when ALL of the following are met:

    Clinical response: Documentation of positive clinical response to Nucala therapy
    Continued concomitant therapy: Will continue Nucala as add-on maintenance therapy in combination with intranasal corticosteroids

    Not receiving other specified biologics; dosing per FDA; reauthorization ≤12 months

    Nucala — Chronic Obstructive Pulmonary Disease (COPD) (initial)

    Nucala is proven/medically necessary when ALL of the following are met:

    Diagnosis and phenotype: Diagnosis of COPD with an eosinophilic phenotype (baseline peripheral blood eosinophils ≥ 300 cells/μL)≥ 300 cells/μL
    Spirometry criteria: Post-bronchodilator FEV1/FVC < 0.7 and post-bronchodilator FEV1 % predicted between 20% and 80%FEV1/FVC < 0.7; FEV1 20–80% predicted
    Exacerbation history: Uncontrolled COPD demonstrated by either ≥2 exacerbations in prior year requiring systemic steroids/antibiotics OR ≥1 exacerbation leading to hospitalization/observation >24 hours
    Optimized maintenance therapy: Exacerbations occurred while on maintenance therapy (triple therapy LAMA+LABA+ICS or dual LAMA+LABA with failure/contraindication/intolerance to ICS); Nucala to be used as add-on to specified maintenance therapy
    No concurrent biologic and prescriber: Not receiving other specified biologics for same indication; dosing per FDA label; prescribed by allergist/immunologist/pulmonologist

    Initial authorization ≤ 12 months

    Reauthorization — Nucala for COPD

    Reauthorization approved when ALL of the following are met:

    Clinical response: Documentation of positive clinical response to Nucala therapy
    Continued concomitant maintenance therapy: Nucala is being used in combination with specified maintenance therapy; not receiving other specified biologics; dosing per FDA label

    Reauthorization ≤ 12 months

    Unproven / Not medically necessary

    Unproven indications: Cinqair, Fasenra, and Nucala are unproven/not medically necessary for: acute bronchospasm; granulomatosis with polyangiitis (Wegener's); microscopic polyangiitis; organ- or life-threatening EGPA; other eosinophilic conditions; status asthmaticus
    Cinqair and Fasenra - COPD: Cinqair and Fasenra are unproven and not medically necessary for COPD

    Covered indications aligned with evidence and labeling

    Covered when supported by evidence from trials and aligned with labeled indications and background therapy:

    EGPA - mepolizumab: Mepolizumab is indicated for adult patients with EGPA; trials demonstrated increased accrued weeks of remission and higher remission rates versus placebo when used with background standard care, with reduced relapse rate and glucocorticoid-sparing effects.clinical trial enrollment criteria apply (e.g., relapsing/refractory EGPA, eosinophilia)

    See trial details for inclusion criteria and endpoints

    EGPA - benralizumab: Benralizumab is indicated for adult patients with EGPA; a phase 3 trial showed noninferiority to mepolizumab for remission in relapsing/refractory EGPA on background prednisone/prednisolone ± immunosuppressive therapy.requires asthma, eosinophilia, relapsing/refractory disease on glucocorticoids

    Noninferiority margin and trial outcomes summarized in evidence

    Severe eosinophilic asthma - benralizumab: Benralizumab indicated as add-on maintenance for severe asthma age ≥6 with eosinophilic phenotype; trials showed reduced exacerbation rates in patients with baseline blood eosinophils ≥300 cells/µL and OCS-sparing in ZONDA.history of ≥2 exacerbations in prior 12 months; elevated eosinophils (trial strata ≥300 cells/µL)

    Dosing schedules and trial strata apply

    Severe eosinophilic asthma - mepolizumab: Mepolizumab indicated as add-on maintenance for severe asthma age ≥6 with eosinophilic phenotype; trials showed fewer exacerbations and OCS dose reductions in patients with blood eosinophils ≥150 or ≥300 cells/µL depending on trial.history of ≥2 exacerbations in prior year or other prespecified eosinophil/biomarker criteria

    Multiple dose regimens studied; 100 mg SC commonly evaluated

    Severe eosinophilic asthma - reslizumab: Reslizumab indicated as add-on for severe asthma age ≥18 with eosinophilic phenotype; trials (Studies I–IV) showed reduced exacerbations in subjects with baseline blood eosinophils ≥400 cells/µL using 3 mg/kg IV every 4 weeks.baseline eosinophils ≥400 cells/µL in pivotal studies; prior exacerbation history required

    Weight‑based IV dosing and age restriction (≥18) apply

    Covered indications aligning with trial populations and FDA labels

    Covered when clinical criteria align with FDA-labeled indications and trial populations

    Severe eosinophilic asthma - general biologic eligibility: Patient has severe asthma uncontrolled despite optimized high-dose ICS-LABA (and other controllers) AND has an eosinophilic phenotype (trial cutoffs vary; guidance suggests ≥150 cells/µL; some reslizumab trials used ≥400/µL) AND documented exacerbation history consistent with trials (e.g., ≥1 exacerbation requiring systemic corticosteroid or hospitalization in prior 12 months or ≥2 moderate exacerbations).see supporting nodes

    References: reslizumab trials, GINA, ERS/ATS

    Agent-specific: Cinqair (reslizumab): Indicated as add‑on maintenance for severe asthma in adults ≥18 with eosinophilic phenotype; trials enrolled patients with eosinophils ≥400/µL and prior exacerbations; monitor for anaphylaxis during and after infusion.age ≥18; eosinophils commonly ≥400/µL in trials

    Chunks 54-55,70

    Agent-specific: Fasenra (benralizumab): Indicated as add‑on maintenance for severe asthma in patients ≥6 years with eosinophilic phenotype; also indicated for EGPA in adults.age ≥6 for asthma indication

    Chunk 71

    Agent-specific: Nucala (mepolizumab): Indicated as add‑on maintenance for severe asthma ≥6 years with eosinophilic phenotype and for multiple eosinophilic conditions including EGPA, HES (≥12 years, disease ≥6 months without non‑hematologic secondary cause), CRSwNP (adults ≥18), and COPD with eosinophilic phenotype in adults; HES trials required ≥1,000 cells/µL and ≥2 flares in prior 12 months.age and indication‑specific per FDA label

    Chunks 56-61,72

    Clinical trial endpoints supporting coverage: Trials showed reductions in exacerbation rates (reslizumab, mepolizumab), improvements in FEV1 in some studies, reduction in HES flares, and reduced need for nasal surgery/systemic steroids in CRSwNP with mepolizumab.N/A

    Chunks 54-61

    Indication-based coverage guidance (Nucala)

    Coverage and clinical context notes for respiratory interleukin biologics in this excerpt

    Nucala FDA indications: Nucala is FDA‑approved for add‑on maintenance treatment of severe asthma with eosinophilic phenotype for patients aged ≥6; also indicated for adult EGPA, HES (≥12 years, ≥6 months disease without identifiable non‑hematologic secondary cause), add‑on for inadequately controlled COPD with eosinophilic phenotype (adults), and CRSwNP (adults ≥18).

    Not indicated for relief of acute bronchospasm or status asthmaticus.

    Medicare and MAO coverage framework

    Medicare / Plan-level coverage considerations

    Medicare coverage status: There is no Medicare National Coverage Determination (NCD) or local LCD/LCA for these agents; Medicare Advantage Organizations may develop their own determinations and may apply Part B step therapy programs or other internal review programs.

    In absence of NCD/LCD, MAO can create determinations using evidence‑based rationale.

    Use of these agents in combination with other biologic therapies for the same therapeutic indication is prohibited. Specifically, concurrent administration of anti‑IL‑5 agents (e.g., reslizumab/Cinqair, benralizumab/Fasenra, mepolizumab/Nucala) with other targeted biologics such as anti‑IgE (omalizumab), anti‑IL‑4 (dupilumab), or TSLP inhibitors (tezepelumab) for the same indication is not allowed and will result in denial of coverage.

    Authorization and prescribing must reflect single‑biologic use for the treatment indication; dosing should follow FDA labeling and prescriptions should be from the required specialty (pulmonology, allergy/immunology, or other specialties listed per indication).

    Concurrent use of Nucala (mepolizumab) with any other biologic for the same indication is not permitted. The policy explicitly excludes combined treatment with other anti‑IL‑5 agents (e.g., Cinqair, Fasenra), anti‑IgE agents (omalizumab), anti‑IL‑4 agents (dupilumab), or TSLP inhibitors (tezepelumab) when used to treat the same disease.

    Providers must document that the patient is not receiving another listed biologic for the same indication at the time of prior authorization submission; failure to do so may result in denial.

    The following uses are considered unproven or not medically necessary due to insufficient evidence from robust randomized controlled trials: acute bronchospasm, status asthmaticus, granulomatosis with polyangiitis (Wegener's), microscopic polyangiitis, organ‑ or life‑threatening EGPA, and other eosinophilic conditions. Cinqair and Fasenra are additionally listed as unproven for COPD.

    Statistically robust randomized controlled trial evidence is required to support use of these biologics in the listed acute or non‑labeled eosinophilic conditions; absent such evidence, these indications are not supported by this policy.

    Use of Cinqair, Fasenra, and Nucala for non‑approved eosinophilic conditions or in acute care settings (for example, acute bronchospasm or status asthmaticus) is considered unproven and/or not medically necessary. Nucala and Cinqair have additional uses listed in their labels for other eosinophilic conditions, but the policy treats these uses as unproven without robust RCT support.

    For chronic indications (e.g., HES, CRSwNP, COPD), coverage only applies when the specific, indication‑based criteria in this policy are met and documented; acute or emergent uses are not covered.

    These biologic agents are not indicated for relief of acute bronchospasm or for management of status asthmaticus. The FDA labeling for Cinqair, Fasenra, and Nucala specifies add‑on maintenance indications for severe eosinophilic asthma and other chronic eosinophilic disorders, and explicitly states that they are not indicated for acute bronchospasm or status asthmaticus.

    Because they are not labeled for acute relief, claims or requests for administration for acute bronchospasm/status asthmaticus will be considered not medically necessary under this policy.

    Requests for therapy will be denied when the patient does not meet the policy’s required elements for the indication. Common reasons for noncoverage include absence of the required diagnosis (e.g., severe asthma, EGPA, HES, CRSwNP, COPD), lack of documented eosinophilic phenotype (e.g., pre‑treatment peripheral blood eosinophils < 150 cells/μL for asthma indications or < 300 cells/μL where specified for COPD), inadequate documentation of disease severity or uncontrolled status, absence of required background controller therapy, or lack of prescribing by an appropriate specialist.

    Prior authorization submissions must include all required clinical documentation (diagnosis, baseline eosinophil counts, exacerbation history, prior controller therapies, and specialist prescriber) to establish medical necessity.

    The policy lists specific indications as not medically necessary when criteria are unmet or when the indication itself is unsupported: examples include acute bronchospasm, vasculitides such as granulomatosis with polyangiitis and microscopic polyangiitis, organ‑ or life‑threatening EGPA, other non‑specified eosinophilic conditions, and status asthmaticus. Additionally, Cinqair and Fasenra are considered not medically necessary for COPD outside the limited circumstances described for Nucala.

    Coverage is limited to FDA‑labeled, evidence‑supported chronic indications and only when the policy’s documented clinical criteria are satisfied.

    Cinqair, Fasenra, and Nucala are explicitly listed as unproven and not medically necessary for the acute and non‑indicated eosinophilic conditions named in this policy (acute bronchospasm, status asthmaticus, vasculitides, organ‑threatening EGPA, other eosinophilic disorders). For indications lacking robust randomized controlled trial data, the policy does not support coverage.

    When considering off‑label uses for eosinophil‑related conditions, reviewers should require high‑quality trial evidence and adherence to the member’s benefit terms; absent that evidence, requests should be denied as not medically necessary.

    Treatment of acute bronchospasm or status asthmaticus with Cinqair, Fasenra, or Nucala is not supported by robust randomized controlled trial evidence. The document notes that statistically robust RCTs are necessary to establish safety and efficacy for these acute uses; until such evidence exists, these agents are considered unproven for acute/emergent management.

    Consequently, administration of these biologics for acute exacerbations should not be authorized and will be considered not medically necessary under this policy framework.

    Billing and Diagnosis Codes

    Referenced biologic products (drug names)NDC | HCPCS | mixed
    Cinqair (reslizumab)provider-administered IV reslizumab — product referenced
    Fasenra (benralizumab)provider-administered SC benralizumab — product referenced
    Nucala (mepolizumab)provider-administered SC mepolizumab — product referenced
    Relevant HCPCS drug codesHCPCS
    J0517Injection, benralizumab, 1 mg
    J2182Injection, mepolizumab, 1 mg
    J2786Injection, reslizumab, 1 mg
    Relevant ICD-10 diagnosis codesICD-10
    D72.11Hypereosinophilic Syndrome
    J31.0Chronic rhinitis
    J32.0Chronic maxillary sinusitis
    J32.1Chronic frontal sinusitis
    J32.2Chronic ethmoidal sinusitis
    J32.3Chronic sphenoidal sinusitis
    J32.4Chronic pansinusitis
    J32.8Other chronic sinusitis
    J32.9Chronic sinusitis, unspecified
    J33.0Polyp of nasal cavity
    1–10 of 17
    1/2
    Applicable HCPCS and ICD-10 codes (group 1)mixed
    J0517Injection, benralizumab, 1 mg.
    J2182Injection, mepolizumab, 1 mg.
    J2786Injection, reslizumab, 1 mg.
    D72.11Hypereosinophilic Syndrome.
    J31.0Chronic rhinitis.
    J32.0Chronic maxillary sinusitis.
    J32.1Chronic frontal sinusitis.
    J32.2Chronic ethmoidal sinusitis.
    J32.3Chronic sphenoidal sinusitis.
    J32.4Chronic pansinusitis.
    1–10 of 20
    1/2
    Applicable ICD-10 codes (group 2)ICD-10
    J45.51Severe persistent asthma with (acute) exacerbation.
    J45.52Severe persistent asthma with status asthmaticus.
    J82.81Chronic eosinophilic pneumonia.
    J82.82Acute eosinophilic pneumonia.
    J82.83Eosinophilic asthma.
    J82.89Other pulmonary eosinophilia, not elsewhere classified.
    M30.1Polyarteritis with lung involvement [Churg-Strauss].
    Biologic agents mentioned (no billing codes provided)mixed
    N/ADocument lists FDA-approved agents Cinqair (reslizumab), Fasenra (benralizumab), Nucala (mepolizumab) but does not provide billing codes in this section.
    Neutral: referenced drug administration codesmixed
    affected codesPolicy references Medicare Part B drugs and programs; specific HCPCS/CPT codes not listed in this excerpt.
    inv-35: Peripheral blood eosinophil threshold — ≥ 150 cells/μL
    Peripheral blood eosinophil thresholdBaseline (pre-treatment) peripheral blood eosinophil level ≥ 150 cells/μL
    Use caseDefines eosinophilic phenotype for severe asthma and eligibility for anti‑IL‑5 therapies
    Guideline supportERS/ATS suggests a blood eosinophil cut‑point ≥150 cells/μL to guide anti‑IL‑5 initiation in adults
    inv-36: HES baseline eosinophil — ≥ 1000 cells/µL within 4 weeks pre-treatment
    HES baseline eosinophil requirementBaseline (pre‑mepolizumab) blood eosinophil level ≥ 1000 cells/µL within the past 4 weeks
    Background therapyPatient must be on a stable dose of background HES therapy at time of measurement (e.g., oral corticosteroid, immunosuppressant, or cytotoxic therapy)
    Trial entry criteriaHES pivotal trial required blood eosinophil ≥1000 cells/µL and ≥2 HES flares in prior 12 months
    inv-37: COPD eosinophil phenotype — ≥ 300 cells/μL
    COPD eosinophilic phenotype cutoffBaseline (pre‑treatment) peripheral blood eosinophil level ≥ 300 cells/μL
    ContextUsed to define eosinophilic phenotype for add‑on Nucala therapy in COPD
    Relation to asthma trialsHigher eosinophil thresholds (e.g., ≥300 cells/µL) were used as strata in benralizumab trials demonstrating greater benefit
    inv-38: COPD spirometry — Post-bronchodilator FEV1/FVC < 0.7 and FEV1 % predicted 20–80%
    Spirometry diagnostic criteria for COPDPost‑bronchodilator FEV1/FVC < 0.7 and post‑bronchodilator FEV1 % predicted between 20% and 80%
    Use in policyRequired along with eosinophilic phenotype and exacerbation history to qualify for Nucala in COPD
    Combined requirementSpirometry abnormality plus eosinophil cutoff and maintenance therapy failure define medical necessity
    inv-39: Blood eosinophil thresholds used in trials — commonly >=150, >=300, or >=400 cells/µL depending on trial/agent
    Common trial thresholdsBlood eosinophil thresholds used in trials commonly include ≥150, ≥300, or ≥400 cells/μL depending on trial and agent
    Agent examplesReslizumab pivotal studies enrolled patients with baseline eosinophils ≥400 cells/µL; mepolizumab trials used ≥150 or ≥300 cells/µL depending on study
    ImplicationPolicy aligns eligibility with trial cut‑points and guideline cut‑points for expected benefit
    inv-40: HES diagnostic eosinophil level — typically >1500 cells/µL sustained for 6 months
    Typical diagnostic level for HESPatients with HES usually have more than 1500 eosinophils/µL in their blood for 6 months or more
    Definition implicationSustained eosinophilia with organ damage and unknown cause supports HES diagnosis
    Epidemiology noteHES is rare; prevalence estimates vary and many variants exist (e.g., myeloproliferative, lymphocytic)
    inv-41: Blood eosinophil thresholds — trial thresholds (reslizumab ≥400/µL; HES trial ≥1,000 cells/µL; ERS/ATS guidance ≥150/µL)
    Reslizumab trial thresholdReslizumab (reslizumab) pivotal trials enrolled patients with baseline blood eosinophils ≥400 cells/µL
    HES trial thresholdHES mepolizumab trial entry required blood eosinophil count ≥1,000 cells/µL
    Guideline cutoffERS/ATS guidance suggests a blood eosinophil cut‑point ≥150 cells/µL to guide anti‑IL‑5 initiation in adults

    Provider Requirements, Prior Authorization, and Documentation

    Prior Authorization

    Provider Requirements, Prior Authorization, and Documentation

    Prior authorization is required for provider-administered interleukin and related biologic therapies (e.g., Cinqair, Fasenra, Nucala). Providers must submit complete clinical documentation to support the requested therapy. Incomplete or missing documentation may result in denial or delay.

    • Document diagnosis, baseline peripheral blood eosinophil count (pre-treatment) and phenotype (e.g., eosinophilic phenotype defined in policy thresholds).
    • Provide objective evidence of disease severity and/or uncontrolled disease (e.g., ACQ/ACT scores, number of exacerbations, OCS bursts, ED visits, hospitalizations, FEV1/FEV1-FVC data).
    • For EGPA, submit documentation of relapsing or refractory disease and required clinical characteristics (history/presence of asthma plus ≥2 typical EGPA features such as eosinophilic vasculitis, perivascular eosinophilic infiltration, eosinophil-rich granulomatous inflammation, neuropathy, pulmonary infiltrates, sino-nasal abnormality, cardiomyopathy, glomerulonephritis, alveolar hemorrhage, palpable purpura, or ANCA positivity).
    • For HES, submit baseline (pre-treatment) blood eosinophil ≥ 1000 cells/µL within past 4 weeks and documentation the patient is on a stable dose of background HES therapy (e.g., oral corticosteroid, immunosuppressive, or cytotoxic therapy) and history of ≥2 HES flares in prior 12 months.
    • For CRSwNP, provide baseline documentation of inadequate response to nasal corticosteroids (≥8 weeks) and conservative therapies (e.g., saline irrigations, intranasal corticosteroids, antileukotriene agents), prior sinus surgery status (e.g., prior surgery within 10 years) or prior systemic corticosteroid use for CRSwNP in previous 2 years, nasal obstruction VAS and endoscopic/CT findings consistent with policy criteria.
    • Confirm therapy will be used as add‑on maintenance and that standard/conservative therapies and other indicated treatments (intranasal/oral corticosteroids, surgery for nasal polyps, optimized inhaled controllers for asthma) have been trialed and failed as appropriate.
    • If requesting Cinqair, document prior biologic therapy trials per step therapy requirement: history of failure to a 4‑month trial of Fasenra or Nucala or documented contraindication/intolerance to them, and history of failure to a 4‑month trial of Tezspire or contraindication/intolerance to Tezspire.
    • Do not combine biologics for the same indication. Document the patient is not receiving concurrent biologic therapy from the prohibited lists (anti‑IL‑5/5R, anti‑IgE, anti‑IL‑4/13, anti‑TSLP agents).
    • Dosing must follow FDA‑approved labeling and drug must be prescribed by an appropriate specialist (e.g., pulmonologist, allergist/immunologist, hematologist, cardiologist, or otolaryngologist depending on indication). Initial authorizations are limited to up to 12 months unless otherwise specified.
    • Therapies used for unproven or not medically necessary indications (e.g., acute bronchospasm, status asthmaticus, Wegener's/granulomatosis with polyangiitis, microscopic polyangiitis, organ- or life‑threatening EGPA, other eosinophilic conditions, and COPD for certain agents) are subject to denial per policy.
    • Check member‑specific benefit plan documents, federal/state mandates, and Medicare Advantage program rules (e.g., Medicare Part B Step Therapy) — benefit terms govern coverage and may impose additional requirements.
    • Ensure medical records (chart notes, lab values, imaging, operative reports) supporting all criteria are submitted with the PA request; missing phenotype/severity documentation or insufficient EGPA documentation may trigger denial.
    Denial Risk

    Denial Risk and Common Triggers

    Prior authorization will be denied when clinical prerequisites are not met or when use is for unproven indications or in disallowed combinations. Common high‑risk denial triggers include missing eosinophilic phenotype or severity documentation, incomplete EGPA diagnostic features, concurrent use of another biologic for the same indication, non‑FDA dosing, and lack of required prior therapy trials (including step therapy for Cinqair).

    • Missing pre‑treatment peripheral blood eosinophil documentation (policy thresholds vary by indication; e.g., ≥150 cells/µL for many severe eosinophilic asthma indications, ≥300 cells/µL for COPD, ≥1000 cells/µL for HES within prior 4 weeks) may result in denial.
    • Insufficient documentation of relapsing/refractory EGPA (absence of required clinical characteristics or histopathology) may result in denial.
    • Requests for therapy in combination with another biologic listed in policy for the same indication (e.g., anti‑IL‑5 with anti‑IL‑5, anti‑IgE, anti‑IL‑4/13, or anti‑TSLP agents) will be denied.
    • Use for conditions listed as unproven/not medically necessary (e.g., acute bronchospasm, status asthmaticus, granulomatosis with polyangiitis, microscopic polyangiitis, organ/life‑threatening EGPA, certain other eosinophilic conditions; and COPD for some agents) will be denied.
    • Cinqair-specific step therapy denials if there is no documentation of failure to a 4‑month trial of Fasenra or Nucala (or documented contraindication/intolerance), and no documentation of failure to a 4‑month trial of Tezspire (or documented contraindication/intolerance).
    • Lack of documentation demonstrating trials of standard therapies prior to biologic (e.g., intranasal/oral corticosteroids, surgical history for CRSwNP; maximally dosed ICS/LABA and other controller therapies for asthma) may lead to denial.
    Documentation Required

    Required Supporting Documentation and Plan Terms

    Documentation and program rules required at the time of PA submission — these items support adjudication and compliance with benefit terms.

    • Submit baseline labs (per‑indication eosinophil counts with collection date) and relevant imaging or endoscopy reports (e.g., nasal endoscopy or sinus CT for CRSwNP).
    • For HES: submit baseline (pre‑treatment) blood eosinophil ≥ 1000 cells/µL within the past 4 weeks and documentation of stable background HES therapy.
    • For CRSwNP: document ≥8 weeks of nasal corticosteroid use pre‑screening, symptom duration ≥12 weeks, endoscopic NPS or CT findings per policy, prior sinus surgery history (if applicable), nasal obstruction VAS scores, and trials of conservative therapies (e.g., saline irrigation, intranasal corticosteroids, antileukotriene agents).
    • Include notation of prior standard therapy trials before biologic initiation (optimized inhaled controller therapy for asthma, systemic corticosteroid courses, and surgical interventions where indicated).
    • Members on Medicare Advantage may be subject to Part B Step Therapy Programs and other Medicare-specific requirements; consult Medicare program materials and the member‑specific plan.
    • Verify member‑specific benefit plan documents for coverage limits, exclusions, or state/federal mandates — plan terms govern and may supersede policy language.

    Clinical Background and Evidence Context

    These biologic therapies target the interleukin‑5 pathway and related mechanisms and are intended as add‑on maintenance treatments for severe eosinophilic diseases. Coverage decisions hinge on demonstration of an eosinophilic phenotype (for asthma, a baseline pre‑treatment peripheral blood eosinophil count of ≥ 150 cells/μL is a common threshold) and evidence of uncontrolled disease despite optimized controller therapy.

    Agent‑specific indications and age limits apply (for example, Nucala and Fasenra have asthma approvals for patients aged ≥6 years, Cinqair is indicated for adults ≥18 years), and FDA labeling clarifies that these agents are not intended for acute bronchospasm or status asthmaticus.

    Key Definitions and Phenotype Criteria

    inv-66: Eosinophilic phenotype — Baseline (pre-treatment) peripheral blood eosinophil level of ≥ 150 cells/μL
    Eosinophilic phenotype definitionBaseline (pre‑treatment) peripheral blood eosinophil level of ≥ 150 cells/μL
    Clinical contextDefines patients with eosinophilic phenotype eligible for anti‑IL‑5 therapies in asthma
    Supporting guidanceERS/ATS and trial criteria reference the ≥150 cells/μL cut‑point though trials may have used higher cutoffs
    inv-67: Relapsing or refractory EGPA — Relapsing: ≥1 EGPA relapse in prior 2 years requiring increased corticosteroids/immunosuppressant or hospitalization; Refractory: inadequate control despite therapy
    Relapsing EGPA definitionRelapsing disease: at least one EGPA relapse within the past 2 years requiring increased corticosteroids or immunosuppressant dose escalation or hospitalization
    Refractory EGPA definitionRefractory disease: failure to attain remission within the prior 6 months after induction therapy
    Documentation requirementDiagnosis must include EGPA features (e.g., asthma and ≥2 typical characteristics) and history of relapsing or refractory disease
    inv-68: Eosinophilic phenotype (COPD) — Baseline peripheral blood eosinophil level ≥ 300 cells/μL
    COPD eosinophilic phenotype cutoffBaseline peripheral blood eosinophil level ≥ 300 cells/μL
    Policy useRequired for Nucala add‑on maintenance therapy in COPD when combined with spirometric and exacerbation criteria
    Trial alignmentEosinophil cutoff aligns policy with populations evaluated in COPD mepolizumab studies
    inv-69: Eosinophilic phenotype (asthma) — Asthma subtype associated with elevated eosinophil levels; estimated in about half of severe asthma patients
    Asthma eosinophilic subtypeAsthma subtype associated with elevated eosinophil levels in blood and airways; roughly half of severe asthma patients exhibit this phenotype
    Therapeutic relevancePatients with this phenotype are more likely to respond to IL‑5 pathway biologics such as mepolizumab, benralizumab, and reslizumab
    Population estimateApproximately 1.2–2.4 million people in the U.S. have severe asthma, and an estimated half of those have eosinophilic phenotype
    inv-70: Hypereosinophilic Syndrome (HES) — Sustained overproduction of eosinophils with organ damage; often >1500 eosinophils/µL for 6 months and unknown cause
    HES definitionSustained overproduction of eosinophils with organ damage; often >1500 eosinophils/µL for ≥6 months and no identifiable non‑hematologic secondary cause
    Clinical implicationsOrgan involvement from eosinophilic infiltration necessitates background therapy; mepolizumab reduces flares in selected patients
    Trial requirementsHES trials excluded FIP1L1‑PDGFRα kinase‑positive disease and required stable background therapy and recent flares
    inv-71: EGPA (Eosinophilic granulomatosis with polyangiitis) — Vasculitic syndrome with asthma, sinusitis, pulmonary infiltrates, neuropathy, and eosinophilic vasculitis; primarily treated with systemic therapy
    EGPA clinical featuresVasculitic syndrome with asthma, sinusitis, pulmonary infiltrates, neuropathy, and eosinophilic vasculitis
    Treatment contextPrimarily treated with systemic glucocorticoids; IL‑5 pathway biologics (mepolizumab, benralizumab) are used for relapsing/refractory disease
    Diagnostic requirementsPolicy requires EGPA diagnosis plus ≥2 typical characteristics and documentation of relapsing or refractory course for biologic eligibility
    inv-72: Uncontrolled / Severe Asthma — Poor symptom control and/or frequent exacerbations (≥2/year) or serious exacerbations (≥1/year requiring hospitalization)
    Uncontrolled / Severe asthma definitionUncontrolled: poor symptom control and/or frequent exacerbations (≥2/year) or serious exacerbations (≥1/year requiring hospitalization). Severe asthma: uncontrolled despite optimized high‑dose ICS‑LABA and other management
    Eligibility implicationBiologic therapy is recommended as add‑on for uncontrolled severe asthma after optimized maximal therapy per GINA
    Objective measuresPoor control examples include ACQ>1.5 or ACT<20, frequent OCS bursts, emergency treatments, or persistent airflow limitation
    inv-73: Eosinophilic phenotype cutoffs — ERS/ATS suggests blood eosinophil cut-point ≥150 cells/µL to guide anti-IL-5 initiation; trials used higher thresholds
    ERS/ATS recommended cut‑pointERS/ATS suggests blood eosinophil cut‑point ≥150 cells/μL to guide anti‑IL‑5 initiation in adults
    Trial variabilityClinical trials frequently used higher thresholds depending on agent (e.g., reslizumab ≥400/µL) so policy accounts for both guideline and trial cut‑points
    Policy applicationUse guideline cut‑point for general eligibility but reference trial cut‑points for agent‑specific evidence and documentation
    inv-74: Nucala (mepolizumab) — FDA-approved monoclonal antibody for add-on maintenance treatment of severe eosinophilic asthma and other labeled indications
    Nucala (mepolizumab) labelingFDA‑approved monoclonal antibody for add‑on maintenance treatment of severe eosinophilic asthma in patients aged ≥6 years and for multiple eosinophil‑driven conditions (EGPA, HES ≥12 years, CRSwNP in adults, COPD in adults)
    Not for acute reliefNot indicated for relief of acute bronchospasm or status asthmaticus
    Trial evidenceMepolizumab reduced exacerbations in asthma trials and reduced HES flares in a 32‑week randomized trial

    Policy Revision History